Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $35.37 Million |
|---|---|
| Enterprise Value | $35.93 Million |
| Earnings per Share | $-4.16 |
| Beta | 1.7 |
| Outstanding Shares | 6,419,222 |
| P/E Ratio | -1.15 |
|---|---|
| PEG | 1.48 |
| Price to Sales | - |
| Price to Book Ratio | 2.48 |
| Enterprise Value to Revenue | 224.11 |
| Enterprise Value to EBIT | -1.61 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.13 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 9.94% |
|---|---|
| Total Invested | $96▼ 100.00% |
| Investors Holding | 1▼ 18.00% |
AzurRx BioPharma, Inc. is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets. Th...